Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic‐phase myelofibrosis

BACKGROUND: The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) and PB ≥4% was associated with a particularly unfavorable prognosis. Ruxolitinib (RUX) is the JAK1/2 inhibitor most used for treatment of MF‐related splenomega...

Descripción completa

Detalles Bibliográficos
Autores principales: Palandri, Francesca, Bartoletti, Daniela, Iurlo, Alessandra, Bonifacio, Massimiliano, Abruzzese, Elisabetta, Caocci, Giovanni, Elli, Elena M., Auteri, Giuseppe, Tiribelli, Mario, Polverelli, Nicola, Miglino, Maurizio, Heidel, Florian H., Tieghi, Alessia, Benevolo, Giulia, Beggiato, Eloise, Fava, Carmen, Cavazzini, Francesco, Pugliese, Novella, Binotto, Gianni, Bosi, Costanza, Martino, Bruno, Crugnola, Monica, Ottaviani, Emanuela, Micucci, Giorgia, Trawinska, Malgorzata M., Cuneo, Antonio, Bocchia, Monica, Krampera, Mauro, Pane, Fabrizio, Lemoli, Roberto M., Cilloni, Daniela, Vianelli, Nicola, Cavo, Michele, Palumbo, Giuseppe A., Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325504/
https://www.ncbi.nlm.nih.gov/pubmed/35363892
http://dx.doi.org/10.1002/cncr.34216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325504/
https://www.ncbi.nlm.nih.gov/pubmed/35363892
http://dx.doi.org/10.1002/cncr.34216

Ejemplares similares